ReviewRheumatic diseases clinics of North America2015
The Epidemiology of Psoriatic Arthritis.
Review in Rheumatic diseases clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06176586 (Investigating the Effects of Mat Pilates Exercises in Patients With Axial Psoriatic Arthritis), which is not on this map. Cited by 224 papers, 16 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Effects of Mat Pilates Exercises in Patients With Axial Psoriatic Arthritis
Who cites it
224 citing papers in PubMed, 16 syntheses or guidelines pooled it, 494 citations in OpenAlex.
- Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review.International journal of molecular sciences · 2026Pooled it
- Diagnostic accuracy of machine learning approaches to identify psoriatic arthritis: a meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.The Cochrane database of systematic reviews · 2025Pooled it
- Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis.Clinical rheumatology · 2024Pooled it
- Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.Rheumatology (Oxford, England) · 2024Pooled it
- Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.Advances in rheumatology (London, England) · 2024Pooled it
- Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.Arthritis research & therapy · 2024Pooled it
- Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis.RMD open · 2024Pooled it
- Pooled it
- Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis.Dermatology (Basel, Switzerland) · 2022Pooled it
- Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis.Annals of medicine · 2021Pooled it
- Psoriatic arthritis and physical activity: a systematic review.Clinical rheumatology · 2021Pooled it
- Dermatologists' Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations.Actas dermo-sifiliograficas · 2020Guideline
- Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.Rheumatology international · 2019Pooled it
- Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2019Guideline
- Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.Arthritis care & research · 2019Guideline
- Trial
- Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies.Journal of clinical pharmacology · 2025Trial
- Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.Rheumatology (Oxford, England) · 2023Trial
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.Annals of the rheumatic diseases · 2022Trial
164 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by joint and entheseal inflammation with a prevalence of 0.05% to 0.25% of the population and 6% to 41% of patients with psoriasis. PsA is a highly heterogeneous inflammatory arthritis. In this review, current knowledge is discussed regarding the epidemiology of PsA, including disease manifestations, classification criteria for adult and juvenile PsA, methods for recognizing early PsA, including use of screening tools and knowledge of risk factors for PsA, and medical comorbidities associated with PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.